Newsfiscal.ai
EyePoint Pharmaceuticals Announces Workforce Reduction and Termination of Pivotal Wet AMD Trials
· Published
Article summary
EyePoint Pharmaceuticals is cutting its workforce by 50% and ending its late-stage clinical trials for wet age-related macular degeneration (AMD) following a second clinical trial failure.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…